Global pharma and biotech's fight against COVID-19: an investment perspective
Mark Brewer, who heads up the life sciences team at UK broker and M&A advisory company, finnCap (LON: FCAP), gives an overview of some of the growth companies that are currently actively working in the fight against coronavirus in an Expert View piece.
As national governments and medical authorities continue to coordinate an unprecedented global response against the COVID-19 pandemic in order to slow its spread and save lives in the immediate term, the long-term battle to defeat the virus is being led by the pharma and biotech sector.
In a rapidly-developing environment, companies and institutions are fast-tracking the research and development of a range therapies to treat the virus and its associated complications, seeking to condense into months that which might normally take years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze